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Schizophrenia is a serious and chronic mental disorder, in which both genetic and environmental factors have a role in the
development of the disease. Neuregulin-1 (NRG1) is one of the most established genetic risk factors for schizophrenia, and
disruption of NRG1 signaling has been reported in this disorder. We reported previously that NRG1/ErbB4 signaling is inhibited
by receptor phosphotyrosine phosphatase-b/f (RPTP b/f) and that the gene encoding RPTPb/f (PTPRZ1) is genetically
associatedwithschizophrenia.Inthisstudy,weexaminedtheexpressionofRPTPb/finthebrainsofpatientswithschizophrenia
and observed increased expression of this gene. We developed mice overexpressing RPTPb/f (PTPRZ1-transgenic mice), which
showedreducedNRG1signaling,andmolecularandcellularchangesimplicatedinthepathogenesisofschizophrenia,including
altered glutamatergic, GABAergic and dopaminergic activity, as well as delayed oligodendrocyte development. Behavioral
analyses also demonstrated schizophrenia-like changes in the PTPRZ1-transgenic mice, including reduced sensory motor
gating, hyperactivity and working memory deﬁcits. Our results indicate that enhanced RPTPb/f signaling can contribute to
schizophrenia phenotypes, and support both construct and face validity for PTPRZ1-transgenic mice as a model for multiple
schizophrenia phenotypes. Furthermore, our results implicate RPTPb/f as a therapeutic target in schizophrenia.
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Introduction
Schizophrenia (MIM 181500) is a serious and chronic mental
disorder with a 1% lifetime prevalence, characterized by
positive symptoms (that is, delusions and hallucinations),
negativesymptoms(thatis,socialwithdrawal,anhedonia,and
blunted affect) and cognitive dysfunction (that is, deﬁcits
in attention, working memory and executive function).
1–3
Population,familyandtwinstudiesindicatethatschizophrenia
is highly heritable, with additional non-genetic factors
involved in the disease.
4,5 On the basis of pharmacological
and postmortem brain studies, it has been argued that
altered neuronal signaling and circuitry, including the gluta-
matergic,
6–8dopaminergic
9–11andGABAergicpathways,
12,13
as well as white matter abnormalities,
14,15 have important
roles in the development of the disease, however, detailed
molecular and cellular mechanism underlying schizophrenia
pathogenesis are still unknown.
Several lines of evidence indicate that abnormalities
in neuregulin-1 (NRG1) signaling, mediated via the ErbB
receptor family, are involved in schizophrenia. Genetic
association of the gene encoding NRG1 (NRG1) with
schizophrenia is one of the most well-replicated ﬁndings
in genetic dissection of schizophrenia.
16–25 NRG1 is a
multifunctional protein that has important roles in develop-
ment of central nervous system,
26 and it has been shown that
NRG1þ/  mice demonstrate several molecular changes
resembling abnormalities observed in schizophrenia, such as
altered glutamatergic,
27,28 dopaminergic
29 and GABAergic
signaling,
30–34aswellasalteredoligodendrocyteandmyelin
35,36
development.
29,37–39 These mice have also shown abnormal
behaviors relevant to schizophrenia.
19,33 Altered expression of
NRG1 mRNA in the postmortem brain of schizophrenia has
been reported
40–42 and recent ﬁnding using cultured lympho-
cytessuggestthatNRG1signalingissuppressedinpatientswith
schizophrenia.
43,44 There is also emerging data implicating
ERBB4 in schizophrenia. Genetic association of ERBB4
20,35
and gene–gene interaction between ERBB4 and NRG1 in
schizophrenia
20,36 and relevant cognitive dysfunction have been
reported.
45–47 In addition, altered expression of ERBB4 in brain
tissue from patients with schizophrenia has been observed.
48
Finally, ErbB4þ/  and transgenic mice harboring dominant
negative form of ErbB4 showed molecular and behavioral
changes relevant to schizophrenia.
19,29
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www.nature.com/tpWe previously reported that a central nervous system-
speciﬁc phosphatase, receptor phosphotyrosine phospha-
tase-b/z (RPTPb/z) is complexed with ErbB4 via MAGI
scaffolding proteins, such that NRG1/ErbB4 signaling is
negatively regulated by RPTPb/z in vitro. We also found that
the PTPRZ1 gene, which encodes RPTPb/z, is genetically
associated with schizophrenia.
49 Recent copy number
variation analyses have identiﬁed deletions in genes coding
for ErbB4 and MAGI2
50 in schizophrenia.
On the basis of these results, we hypothesized
that increased expression of RPTPb/z would inhibit NRG1
signaling in vivo, thus, leading to schizophrenia phenotypes.
Todirectlytestthisidea,weexaminedtheexpressionlevelsof
RPTPb/z in the brains of patients with schizophrenia, and
developed and characterized a mouse overexpressing
RPTPb/z. To generate the mouse we used a bacterial artiﬁcial
chromosome (BAC) transgenic approach that has robust and
stableexpression,withexpressionregulatedunderthecontrol
of human cis elements, and hence closest to the native state.
Materials and methods
Postmortem human brain specimens. Total RNA from
dorsolateral prefrontal cortex of 105 samples was provided
by the Stanley Foundation (35 each for schizophrenia,
bipolar disorder and healthy controls). The three diagnostic
groups were matched by age, sex, race, postmortem interval
(PMI), pH, side of brain, mRNA quality, smoking status and
lifetime antipsychotics dose. Detailed demographic information
is available (http://www.stanleyresearch.org/dnn/Portals/0/
Stanley/Array%20Collection%20Demographic%20Details%
20Chart-Final.pdf). cDNA was synthesized using the high-
capacity cDNA reverse transcription kit (Applied Biosystems,
Carlsbad, CA, USA). Primers for short and long form of RPTPb
and four endogenous controls (ACTB, GAPD, GUSB and
PPIA) were designed using the software provided for
the Universal Probe Library system (Roche Applied
Science; https://www.roche-applied-science.com/sis/rtpcr/upl/
acenter.jsp). Analysis of variance (ANOVA) with Tukey’s post
hoc tests was used for group comparison.
Mice. All animal procedures were approved by the Insti-
tutional Animal Care and Use Committee of Mount Sinai
School of Medicine and the James J Peters Veterans Affairs
Medical Center. Human BAC RP11-367M11, containing the
entire PTPRZ1 gene was introduced to C57BL/6xC3H F1
hybrid mice and the allele was maintained on a C57Bl6
background. The BAC is 180kb in length and with ﬂanking
genomic sequences of 110 and 42kB around the PTPRZ1
gene. The human gene codes for a protein that shares 85%
identity and 82% similarity with the mouse gene product.
In situ hybridization. In situ hybridization was performed
using digoxygenin-labeled cRNA probes, with sequence
corresponding to 5228–5746bp of mouse cDNA for
RPTPb/z (NM_001081306). Sense and antisense probes
were synthesized and digoxygenin-labeled by in vitro
transcription using Sp6 and T7 RNA polymerase (Roche,
Basel, Switzerland). In situ hybridization was performed
using IsHyb in situ hybridization kit (BioChain, Hayward,
CA, USA) on 20-mm thick sagittal cryosections, according to
the manufacturer’s protocol.
NRG1 stimulation in hippocampal slices. A NRG1
stimulation assay was performed as previously described.
51
Hippocampi were dissected and 200-mm thick slices were
prepared using a tissue chopper (Vibratome, Bannockburn,
IL, USA). Slices were incubated with 200ngml
 1 of
recombinant human neuregulin (NRG1-beta EGF domain,
R&D systems, Minneapolis, MN, USA) or vehicle in ice-cold
Krebs-Ringer solution containing 118mM NaCl, 4.8mM KCl,
1.3mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4,2 5 m M
NaHCO3,1 0 m M glucose supplemented with complete pro-
tease EDTA-free inhibitor tablets (Roche Applied Science,
Penzberg, Germany) and protein phosphatase inhibitor set
(Millipore, Temecula, CA, USA) (pH 7.4) with aeration. After
20min of stimulation, ice-cold EGTA was added to terminate
the reaction. Tissue was then homogenized in lysis buffer
(150mM NaCl, 20mM Tris-HCl, 10% glycerol, 5mM EDTA
and 1% NP-40) supplemented with protease and phos-
phatase inhibitors, and separated on 10% SDS-PAGE gels.
Phosphorylation of extracellular signal-regulated kinase
(ERK) was normalized to ERK levels. ANOVA with Tukey’s
post hoc tests was used for group comparisons.
Quantitative PCR assays. Total RNA was isolated and
cDNA was prepared using the high-capacity cDNA archive kit
(Applied Biosystems). The mRNA levels of the target genes
were measured by qPCR using the Roche Universal Probe
Library system (Roche Applied Science, Indianapolis, IN,
USA). Four endogenous control genes (Ppia, Actb, Gusb and
B2m) were also analyzed for reference. The ABI Prism 7900
sequence detection system (Applied Biosystems) was used
for the PCR reaction. Relative expression levels for control
sample were calculated with qBase software (http://medgen.
ugent.be/qbase/).
52 Unpaired t-tests were used for group
comparisons.
Western blotting. Western blotting was performed according
to standard protocols. The antibodies and their concentration
used were as follows: RPTPb (mouse monoclonal; 1:250;
Molecular Probes, Eugene, OR, USA), phosophotyrosine-ERK
(SC-7383; mouse monoclonal, 1:200, Santa Cruz Bio-
technology, Santa Cruz, CA, USA), ERK (SC-1647; mouse
monoclonal, 1:1000, Santa Cruz Biotechnology), NR2B
(rabbit polyclonal; 1:1000; R&D Systems), phospho-NR2B
(rabbit polyclonal; 1:1000; R&D Systems), GSK3b (mouse
monoclonal, 1:2000, Transduction Laboratories, Franklin
Lakes, NJ, USA), GSK3b phosphorylated at Ser9 (rabbit
polyclonal, 1:1000, Cell Signaling, Danvers, MA, USA).
Electrophysiology. Sections were prepared as described
above and electrophysiology was carried out as we have
recently described.
53,54 In brief, individual slices were placed
in a submerged recording chamber and were perfused
with recording solution at a rate of 1–2mlmin
 1. Schaffer
collateral–commissural ﬁbers were stimulated every 20s.
Stimulus intensity was adjusted to evoke 30–40% maximal
stimulation, and the initial slopes of ﬁeld excitatory
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recordings. Long-term potentiation was induced by either
tetanic or theta-burst stimulation. The responses were
divided by the initial slope of the ﬁrst ﬁeld potential to
normalize the data. Tetanic stimulation consisted of ﬁve
trains of 100Hz stimulation, lasting 200ms at an intertrain
interval of 10s. Synaptic fatigue was studied by measuring
the synaptic responses during the ﬁrst high-frequency train.
Theta-burst stimulation consisted of 10 trains of four pulses
delivered at a frequency of 100Hz separated by 200ms.
Immunohistochemistry. Mice were deeply anesthetized
and perfused intracardially with 4% (parvalbumin (PV)
staining) or 2% (oligodendrocyte staining) paraformal-
dehyde in 0.1 M phosphate buffer, pH 7.2. The brains were
removed, postﬁxed overnight in the same solution at 41C and
cut into 25-mm thick sagittal sections. Sections were then
incubated in blocking buffer PGBA (0.1 M phosphate buffer,
0.1% gelatin, 1% bovine serum albumin, 0.002% sodium
azide) containing 10% normal goat serum for 30min and
then incubated overnight at room temperature with primary
antibodies. Primary antibodies and their concentration used
were as follows: PV (mouse monoclonal; 1:1000, Millipore),
NG2 (rabbit monoclonal; 1:200; Millipore) and CC1/APC
(mouse monoclonal; 1:50; EMD Bioscience, San Diego, CA,
USA). After rinsing in phosphate-buffered saline, sections
were incubated with the relevant secondary antibodies
(goat anti-mouse IgG-HRP, 1:250, Santa Cruz
Biotechnology for PV, Alexa Fluor 488 goat anti-mouse for
CC1/APC, Alexa Fluor 555 donkey anti-rabbit for NG2, both
1:10000, Invitrogen, Carlsbad, CA, USA). 4’,6-Diamidino-2-
phenylindole (1:1000; Molecular Probes) was used as a
nuclear counterstain. Parvalbumin-positive cells were
counted using Zeiss Axiovision2 (Zeiss, Oberkochen,
Germany) and Stereo investigator software (MBF
Bioscience, Williston, VT, USA). A minimum of four
sections per mouse and three mice were evaluated for the
quantiﬁcation. Student’s t-tests were used for comparisons.
Confocal images of NG2 and CC1/APC-positive cells were
obtained using a Zeiss LSM 510 Meta confocal laser-
scanning microscope (Zeiss). Optical sections of confocal
epiﬂuorescence images were sequentially acquired with
LSM5 Image Browser software (Zeiss). Immunoreactive
cells for NG2 and CC1/APC were counted with the ImageJ
cell counting plug-in (http://rsbweb.nih.gov/ij/). A minimum of
three sections per mouse and three mice were evaluated for
the quantiﬁcation. w
2-tests were used for group comparisons.
High-performance liquid chromatography. Dopamine,
homovanillic acid and 3,4-dihydroxyphenylacetic acid
levels were measured as previously described,
55 using an
isocratic high-performance liquid chromatography system
with electrochemical detection, consisting of a pump (ESA
model 582, ESA, Chelmsford, MA, USA), automatic injector
(ESA model 542 autosampler) and a Coulochem III detector
(ESA) in conjunction with a guard cell (ESA model 5020) and
an analytical cell (ESA model 5014B). Cell potentials were
set at 350, 150 and 220mV for the guard, E1 and E2 cells,
respectively. A volume of 25ml per sample was injected with
a ﬂow rate of 0.6mlmin
 1, and passed through a 150-mm
column (ESA model MD-150X3.2) with a particle size of
3mm and pore size of 12nm. The mobile phase consisted of
10% acetonitrile, 90mM NaH2PO4, 1.7mM 1-octane sulfonic
acid, 50mM citric acid and 50mM EDTA, pH 3. Data were
collected and analyzed using the EZStart software (Agilent
Technologies, Santa Clara, CA, USA). Standards were run in
parallel. Unpaired t-tests were used for group comparisons.
Behavioral analyses. Three cohorts of transgenic mice and
wild-type littermate controls were studied. Each cohort
contained 20 transgenic mice and 20 wild-type animals
(10 males and 10 females for each genotype). Behavioral
testing was performed in the Mouse and Rat Phenotyping
Shared Research Facility of Mount Sinai School of Medicine
located at the James J Peters VA Medical Center, Bronx, NY,
USA. Animals were bred at the Mount Sinai School of
Medicine and transferred to the Veterinary Medical Unit at
the James J Peters VA Medical Center for behavioral testing
at 10 weeks of age. After transfer, animals were singly
housed and allowed an acclimation period before initiation of
testing, which begun at 14–16 weeks of age. All mice were
housed in standard clear plastic cages at a constant
temperature of 21–221C, with rooms kept under 12-h light/
dark cycles with lights switched on at 0700h. Access to food
and water was ad libitum. Animals were housed on racks in
random order to prevent rack position effects. Testing was
performed by a single investigator blinded to the genotype of
the animals.
Open-ﬁeld test. Open-ﬁeld testing was performed as
previously described.
56 Mice were brought into the experi-
mental room and were allowed to acclimate for 1h before
testing. Each mouse was placed for 30min in a square open-
ﬁeld box under low lighting conditions. An automated infrared
beam array system measured locomotion in the center and
periphery of the test arena. Experimentally naive mice were
used for all experiments and activity data were collected in
5-min intervals over the 120-min open-ﬁeld session. Where
indicated, MK-801 (0.3mgkg
 1) was injected intra-
peritoneally at 25min before behavioral testing. Similarly,
amphetamine (2mgkg
 1) was injected intraperitoneally at
25min before behavioral testing for ﬁve consecutive days.
Total distance traveled was analyzed with two-way ANOVA
(genotype and treatment) for the study with MK-801. Total
distance traveled during the ﬁrst 40min was compared by
using a three-way ANOVA (genotype, day (repeated
measure) and treatment) for the study with amphetamine.
Sphericity was assessed using the Mauchly test.
Prepulse inhibition test. Prepulse inhibition was assessed as
previously described.
56 Mice were brought into the experi-
mental room and were allowed to acclimate for a minimum of
1h before testing. Mice were individually placed in a startle
enclosure in the startle chamber with a background white
noise of 70dB and were left undisturbed for 10min. Then a
session was started that consisted of 10 trials of each
condition (no discrete stimulus, prepulse only, prepulse-pulse
and pulse only) presented in a pseudorandomized order.
Prepulse–pulse trial started with a 50-ms null period,
followed by a 20-ms prepulse white noise of 72dB. After a
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120dB white noise), followed by a 290-ms recording time.
The total duration of each trial was 500ms. The formula
100 ((startle response on acoustic prepulseþpulse
stimulus trials/pulse stimulus response alone trials) 100)
was used to calculate percent prepulse inhibition. Unpaired
t-tests were used for group comparison.
Light/dark transition test. Light/dark transition testing was
performed as previously described.
56 Mice were placed in
the dark side of a two-chamber light/dark apparatus and were
allowed to move freely between the two chambers with the
door kept open for 10min. The total number of transitions
and time spent in each side were recorded. Unpaired t-tests
were used for group comparisons.
Social interaction. Social interaction was tested using a
three-chamber social interaction and recognition test.
57 The
subject was offered a choice between investigating an
unfamiliar mouse and a novel object. Interaction time was
collected in 5-min segments for each trial. Unpaired t-tests
were used for group comparisons.
Eight-arm radial maze test. Working memory was measured
by win–shift task using an eight-arm radial maze.
58 Mice
were food-restricted to 80–85% of their free-feeding weights.
Mice were ﬁrst habituated to an eight-arm radial maze for
10 days by freely foraging for food rewards located at the end
of the maze arms. Training was given during daily trials for
10 days that consisted of two phases. During the ﬁrst phase,
mice were put in the center of the maze and four random
arms were opened. The animals then had 5min to collect all
of the food rewards located at the end of the arms. The mice
were then removed into a holding chamber for 1min, and the
center and arms of the maze were cleaned with 70% ethanol.
During the second phase, the mice were returned to the
center of the maze and all eight arms of the maze were
opened. However, only the four previously unopened arms
contained food reward for which the animals had 5min to
retrieve. During testing, the delay between phases was
increased from 1min to 5, 30 and 60min on consecutive
days. Errors were classiﬁed as within-phase (re-entries into
target arms) or across-phase (entries into arms baited in the
ﬁrst phase). Data were analyzed for each error type by using
two-way repeated measures ANOVA.
Conditional fear conditioning test. For contextual fear
conditioning, the conditioning chamber (Coulbourne
FreezeFrame system, White Hall, PA, USA) consisted of a
metal and plexiglass chamber (7 7 1200) equipped with a
grid ﬂoor for delivery of the conditioned stimulus and an
overhead camera to monitor movement and freezing. The
conditioning chamber was placed inside a soundproof
isolation cubicle. Training occurred in the dark with
background noise generated by a small fan. Each mouse
was placed inside the conditioning chamber for 2min before
delivery of a 2s foot shock (0.6mA) accompanied by a white
house-light. Each mouse remained in the chamber for an
additional 60s after which another foot shock was given.
Each mouse was returned to its home cage after another
30s. Freezing was deﬁned as a lack of movement (except for
respiration). Baseline freezing was measured during 0–
2mins of the training day. Contextual fear memory was
determined at 24h after training by measuring freezing
during a 3-min test in the conditioning chamber. Unpaired t-
tests were used for group comparisons.
Statistical analysis. Statistical analyses were performed
using SPSS 16.0 (SPSS, Chicago, IL, USA). The results
were expressed as mean values±s.e.m. Statistical signi-
ﬁcance was set at level of 0.05.
Results
Increased expression of RPTPb/f in schizophrenia. We
had previously observed a genetic association of PTPRZ1
with schizophrenia and were interested in assessing whether
expression of the gene product RPTPb/z might be altered in
schizophrenia as further evidence that it may contribute to
pathogenesis. Analysis by qPCR showed increased
expression of RPTPb/z in the dorsolateral prefrontal cortex
of schizophrenia (Figure 1) (ANOVA with Tukey’s post hoc
tests, Po0.05). Although the samples were matched on
these measures, we also carried out multiple regression
analysis which showed that possible confounding factors
including PMI, brain pH, brain side, smoking status and
lifetime antipsychotic dose did not affect expression of
RPTPb/z (data not shown).
Generation of PTPRZ1-transgenics. On the basis of the
postmortem brain data above, we generated mice
overexpressing human RPTPb/z by introducing a BAC,
59
which included the entire human PTPRZ1 gene (RP11-
367M1). The PTPRZ1-transgenics were viable and showed
*
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Figure 1 Elevated RPTPb/z expression in schizophrenia. Analysis by qPCR
showed increased expression of the RPTPb/z-short form in the dorsolateral
prefrontal cortex of patients with schizophrenia compared with controls. n¼35 for
each diagnostic group. Data represent mean±s.e.m. *Po0.05. Error bars
represent s.e.m.
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hippocampal cytoarchitecture. In situ hybridization using a
probe that recognizes both human and mouse transcripts of
PTPRZ1 demonstrated that expression of PTPRZ1 was
increased in the transgenics but the regional distribution
pattern was similar between the transgenics and wild-type
littermates (Figure 2a). We also conﬁrmed that BAC
transgenesis resulted in B50% increase in expression of
both RPTPb/z mRNA and protein (Supplementary Figures
S1a–c).
Inhibition of NRG1 signaling in PTPRZ1-transgenics. To
determine whether increased expression of RPTPb/z led
to decreased NRG1 signaling, hippocampal slices were
prepared from the PTPRZ1-transgenics and littermate
controls and stimulated with NRG1. As we predicted based
on our prior in vitro studies,
49 stimulation increased levels of
phosphorylated ERK in wild-type mice, but not in transgenic
littermates (Figure 2b) (ANOVA with Tukey’s post hoc tests,
Po0.001).
Reduced GABA signaling in PTPRZ1-transgenics. One
of the most established ﬁndings from postmortem brain
studies of schizophrenia is the reduced expression of GAD67
in the prefrontal cortex of patients, and this change has been
attributable to a reduced number of PV-positive cells in this
region.
60,61 It has also been demonstrated that NRG1/Erbb4
signaling controls the development of inhibitory circuits in
the brain, and that reduced signaling suppresses expression
of GAD67 in interneurons,
32 providing a mechanistic
link between altered NRG1 signaling and reduced GABA
signaling in schizophrenia.
21 Interestingly, we found reduced
expression of GAD67 in the medial prefrontal cortex
of PTPRZ1-transgenic mice, when examined by qPCR
(Figure 3a) (unpaired t-test, Po0.05). In addition, we
observed that the numbers of PV-positive neurons were
signiﬁcantly reduced in this region of the PTPRZ1-
transgenics, as compared with wild-type littermates
(Figure 3b) (unpaired t-test, Po0.05).
Increased dopamine signaling in PTPRZ1-transgenics.
We next evaluated dopaminergic activity in PTPRZ1-
transgenic mice. Dopamine abnormalities are considered
core features of schizophrenia, given the molecular targets of
antipsychotics and that elevated dopamine signaling
precedes the onset of schizophrenia and can lead to
cognitive dysfunction.
62 We found B40% increase in the
levels of dopamine, 3,4-dihydroxyphenylacetic acid and
homovanillic acid in the striatum in the transgenics
compared with wild-type littermates (Figure 3c) (unpaired t-
test, Po0.05). Analysis of qPCR showed overexpression of
the dopamine D2 receptor in this region (Figure 3d) (unpaired
t-test, Po0.001). These ﬁndings are of interest in light of a
recent study showing that disruption of NRG1/Erb signaling
in oligodendrocytes induces hyperdopaminergia in the
striatum.
29
Levels of phosphorylated GSK3b, a key mediator of D2
receptor signaling, were signiﬁcantly reduced, which could
be reversed by clozapine (Supplementary Figures S2a, b).
Amphetamine treatment induces synaptic dopamine release,
and can cause psychotic symptoms in healthy controls while
exaggerating symptoms in patients with schizophrenia.
63 The
PTPRZ1-transgenics showed an increased response to
amphetamine, consistent with enhanced dopaminergic
activity in these mice (Figure 3e) (three-way ANOVA
(genotype, day(repeatedmeasure)and treatment), Po0.05).
Altered NMDA signaling in PTPRZ1-transgenics. NRG1
also has an important role in glutamatergic neuro-
transmission,
21 previously implicated in psychosis and
schizophrenia in part because non-competitive agonists
of the N-methyl-D-aspartate receptors induce psychotic
features resembling schizophrenia.
6 One effect of NRG1
signaling is the enhanced phosphorylation of the NR2B
subunit, and this phosphorylation is attenuated in
heterozygous Nrg1- and Erbb4-deﬁcient mice (Nrg1þ/ 
and Erbb4þ/ )
28 and reduced phosphorylation may
contribute to N-methyl-D-aspartate receptor dysfunction in
schizophrenia. Phosphorylation of NR2B was signiﬁcantly
reduced in the hippocampus of the PTPRZ1-transgenics
(Figure 4a) (unpaired t-test, Po0.001), without
a
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Figure 2 Generation and validation of PTPRZ1-transgenics. (a) Increased
RPTPb/z expression in PTPRZ1-transgenics. In situ hybridization was carried out
on wild-type and transgenic littermates. Lower magniﬁcation (top) and higher
magniﬁcation (bottom) images demonstrate increased expression in the
transgenics, with similar expression patterns of PTPRZ1 in both. (b) Reduced
NRG1 signaling in PTPRZ1-transgenics. Hippocampal slices of wild-type mice and
PTPRZ1-transgenics were dissected and incubated with recombinant human
neuregulin (NRG1) or vehicle in ice-cold Krebs-Ringer solution. Phosphorylation
levelsof ERK,adownstream signalingmoleculeofNrg1,wasmeasuredbywestern
blotting. Left, representative experiment; right, quantiﬁcation (mean±s.e.m.) of
three experiments. WT, wild-type mice; TG, transgenic mice. ***Po0.001.
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NMDA or AMPA receptors (Supplementary Figures S3a, b).
PTPRZ1-transgenics showed increased locomotor
activity when challenged with the N-methyl-D-aspartate
receptor antagonist MK801 (Figure 4b) (unpaired t-test,
Po0.05), consistent with altered glutamate signaling in
these mice.
As intact glutamatergic transmission is necessary for long-
term potentiation, we next measured long-term potentiation
inthesemiceandfoundthatlong-termpotentiationinducedby
either tetanus or theta-burst stimulation was signiﬁcantly
reduced in the PTPRZ1-transgenic mice (Figure 4c)
(unpaired t-test, Po0.05), similar to what has been reported
in Nrg1þ/  mice.
28
Delayed oligodendrocyte development in PTPRZ1-
transgenics. White matter and oligodendrocyte
abnormalities have been implicated in schizophrenia
14,64
and NRG1 has been implicated in myelination.
29 RPTPb/z is
expressed in oligodendrocytes, including adult oligo-
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Figure 3 Reduced GABA and increased dopamine signaling in PTPRZ1-transgenics. (a) Reduced expression of GAD1 in the medical prefrontal cortex of PTPRZ1-
trangenics. Data represent mean±s.e.m. for expression of GAD1 determined by qPCR. (b) Decreased numbers of parvalbumin (PV)-positive cells in the medical prefrontal
cortex of PTPRZ1-trangenics. Upper, representative images of the staining pattern; lower, quantiﬁcation of the number of cells stained (mean±s.e.m.). WT, wild-type mice;
TG, transgenicmice.(c)Elevatedlevels ofdopamine andmetabolitesin PTPRZ1-trangenics.Levelsof dopamine,3,4-dihydroxyphenylaceticacid andhomovanillicacid were
assessed by high-performance liquid chromatography. Data represent mean±s.e.m. (d) Increased expression of Drd2 in the striatum of PTPRZ1-transgenics. Gene
expression was determined by qPCR and error bar represents s.e.m. (e) Enhanced amphetamine induced locomotion in PTPRZ1-trangenics (Po0.001). Amphetamine
(2mgkg
 1)wasinjectedintraperitoneallyat25minbeforeopen-ﬁeldtestingforﬁveconsecutivedays.Datarepresentmean±s.e.m.WT,wild-typemice;TG,transgenicmice.
*Po0.05; ***Po0.001.
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Translational Psychiatrydendrocyte progenitors, and RPTPb/z activity inhibits the
differentiation of these cells.
65 PTPRZ1-trangenics showed a
transient reduction in expression of oligodendrocyte- and
myelin-related genes up to 3 weeks of age (Figures 4d and e)
(unpaired t-test, Po0.05 for CLDN11, CNP1, Mag, Mbp,
Mobp and Plp1, Po0.01 for Sox10 at 2 weeks of age;
Po0.05 for CLDN11, Mbp, and Mobp, Po0.01 for
Sox10 at 3 weeks of age). Immunohistochemical analyses
demonstrated a delay in the development of oligodendrocyte
lineage cells in the transgenic animals (Figure 4f)
(w
2-test, Po0.001).
Schizophrenia-related behavioral alterations in PTPRZ1-
transgenics. PTPRZ1-transgenics showed reduced
prepulse inhibition of startle (Figure 5a) (unpaired t-test,
Po0.05), reﬂecting sensory gating abnormalities that are
also observed in schizophrenia.
66 Furthermore, prepulse-
elicited reactivity, considered to be more speciﬁc to psychotic
symptoms of schizophrenia,
66 was signiﬁcantly reduced
in the transgenics (Figure 5b) (unpaired t-test, Po0.05).
Importantly, the PTPRZ1-transgenics showed impaired
working memory—considered to be a core cognitive
dysfunction in schizophrenia—as shown by increased
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Figure 4 Altered N-methyl-D-aspartate signaling and delayed oligodendrocyte development in PTPRZ1-transgenics. (a) Reduced phosphorylation of NR2B in PTPRZ1-
transgenics. Left, representative experiment; right, quantiﬁcation (mean±s.e.m.) of three experiments. (b) Enhanced MK-801 induced locomotion in PTPRZ1-trangenics.
MK-801 (0.3mgkg
 1) was injected intraperitoneally at 25min before behavioral testing. Data represent mean±s.e.m. (c) Impaired long-term potentiation in PTPRZ1-
trangenics. Long-term potentiation was induced either by a high-frequency stimulus or theta-burst stimulus. In both cases there was reduced long-term potentiation in
the transgenics (Po0.05). WT, wild-type mice; TG, transgenic mice. Error bar represents s.e.m. (d, e) Reduced expression of oligodendrocyte- and myelin-related
genes in 14- (d) and 21- (e) day-old PTPRZ1-transgenics. Data represent mean±s.e.m. for gene expression determined by qPCR. (f) Delayed maturation of
oligodendrocytes in PTPRZ1-transgenics. The corpus collosum was stained with markers for immature (NG2) and mature oligodendrocytes (CC1) in 14-day- (P14),
21-day- (P21) or 2-month (2M)-old mice. Left, representative confocal images; right, quantiﬁcation (mean±s.e.m.) of three animals. Scale bar¼20mm. WT, wild-type mice;
TG, transgenic mice. *Po0.05; **Po0.01; ***Po0.001.
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Translational Psychiatryerrors in the win-shift task using the eight-arm radial maze
test (Figures 5c and d) (two-way repeated measures
ANOVA, Po0.05). In addition, the transgenics were
impaired in a contextual fear conditioning test, suggesting
problems in associative learning and memory (Figure 5e)
(unpaired t-test, Po0.05). Other measures associated
with the schizophrenia phenotype were also subtly altered,
including increased locomotor activity, reduced social activity
and increased anxiety (Supplementary Figures S4a–c).
Discussion
We observed that RPTPb/z expression is upregulated in
schizophrenia.Onecaveatwithour studyisthatwemeasured
expression of RPTPb/z only in dorsolateral prefrontal cortex
because of the limited availability of other tissue, therefore,
we cannot conclude that RPTPb/z is overexpressed more
broadly; hence, our ﬁnding requires replication in an inde-
pendent cohort and with additional brain regions. Interest-
ingly, since we initiated this study, an additional study has
reported increased expression of this gene in the amygdala in
independent samples in schizophrenia.
67
We observed increased expression of RPTPb/z could
inhibit NRG1 signaling in slices and led to several molecular
features that capture aspects of schizophrenia, including
reduced GABAergic signaling, enhanced dopamine signaling
in the striatum and altered NMDA signaling, as well as
behavioral and cognitive changes in mice. Furthermore, we
observed delayed oligodendrocyte and myelin development
in the PTPRZ1-transgenics, which reﬂects an additional
deﬁcit observed in schizophrenia. Taken together, our results
indicate that increased expression of RPTPb/z in vivo
captures many key aspects of the molecular, cellular,
behavioral and cognitive phenotypes of schizophrenia.
The mechanisms by which PTPRZ1 overexpression leads
to these multiple abnormalities are currently unknown but
some relationships can be proposed. On the basis of recent
studies showing that ErbB4 is predominantly expressed in
interneurons in adult mouse brain
32,33 and that GABAergic
dysfunction induced elevated dopaminergic activity,
68,69 one
could speculate that increased expression of RPTPb/z may
inhibit ErbB4 function in interneurons leading to subsequent
changes, including GABAergic dysfunction and elevated
dopaminergic activity.
Wealsofoundadditionalmolecularandbehavioralchanges
relevant to glutamatergic signaling in the PTPRZ1-trans-
genics, however, effects of NRG1 on this pathway have
not yet been completely clariﬁed.
70 There is a possibility
that these changes in glutamate signaling might be a
consequence of direct interaction of RPTPb/z with synaptic
proteins such as PSD95
71 and MAGIs
72 rather than via the
NRG1 pathway. It has been proposed that insults affecting
myelination in early life could induce imbalances in the
development of brain circuits relevant to schizophrenia
pathogenesis,
73 hence, one can also speculate that delays
in oligodendrocyte development in the transgenic animals
will have impact on the development of the circuitry
underlying glutamateric, GABAergic and/or dopaminergic
signaling.
Some postmortem brain studies have suggested that
NRG1 signaling is upregulated in schizophrenia.
42,51,60
Interestingly, a recent study using transgenic mice, which
overexpress NRG1, demonstrated that even though these
transgenics showed molecular changes in the opposite
direction to the ﬁndings from postmortem brain studies
of schizophrenia—including increased PV-positive cells,
increased expression of oligodendrocyte markers and de-
creased expression of dopamine synthetic enzymes—they
manifestedalmostthesamebehavioralphenotypesasNrgþ/
  or ErbB4þ/  mice.
74 It is therefore possible that for certain
critical pathways, over or under activity are equally disruptive
and can produce overlapping end results.
Many schizophrenia-relevant phenotypes have been de-
ﬁned in mice (
75,76; and see Supplementary Table S1) and
extensive efforts have been made to develop mouse models
with face, construct and predictive validity in schizophrenia.
We have demonstrated that PTPRZ1-transgenic mice
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Figure 5 Behavioral and cognitive alterations in PTPRZ1-transgenics.
(a, b) Blunted prepulse inhibition in PTPRZ1-trangenics. Prepulse inhibition was
measured with a 78-dB prepulse stimulus. The test showed reduced prepulse
inhibition (a) and prepulse-elicited reactivity (b) in the PTPRZ1-transgenics. Data
represent mean±s.e.m. (c, d) Deﬁcits in working memory in PTPRZ1-trangenics.
Eight-arm radial maze testing showed increasedwithin phase (c) and across phase
(d) error numbers in the PTPRZ1-transgenics. Data represent mean±s.e.m.
(e) Impaired associative learning and memory in conditional PTPRZ1-trangenics.
Fearconditioningtest showedreducedfreezing timeat 24h after training.WT, wild-
type mice; TG, transgenic mice; *Po0.05; ***Po0.001.
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Translational Psychiatrydemonstrate reduced NRG1/Erb signaling, which in turn is
associated with many of these schizophrenia phenotypes
(Supplementary Table S1), making it a potentially useful
model for understanding the biology of schizophrenia. The
diverse phenotypes affected in the PTPRZ1-transgenic mice
indicate that they satisfy face validity for multiple facets of
schizophrenia. The genetic association of PTPRZ1 with
schizophrenia that we previously reported, and the elevated
expression of RPTPb/z in the brain in schizophrenia shown
here indicate that the model also has construct validity for
schizophrenia. More studies will be needed to assess the
degree to which the PTPRZ1-transgenic model has predictive
validity, although we are encouraged to see that dopamine
signaling abnormalities were reversed by clozapine. The
elevated expression of RPTPb/z in the brain in schizophrenia
indicates that the development of speciﬁc inhibitors of
RPTPb/z activity and/or function represents a novel thera-
peutic approach for schizophrenia.
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